Working… Menu

Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01347294
Recruitment Status : Unknown
Verified February 2017 by Rune Andersen, Oslo University Hospital.
Recruitment status was:  Recruiting
First Posted : May 4, 2011
Last Update Posted : February 20, 2017
Information provided by (Responsible Party):
Rune Andersen, Oslo University Hospital

Brief Summary:
The purpose of this study is to determine the effectiveness of bleomycin, fibrovein and bleomycin and fibrovein in the treatment of venous malformation.

Condition or disease Intervention/treatment Phase
Venous Malformation Drug: Bleomycin Drug: Fibrovein Drug: Bleomycin + Fibrovein Phase 4

Detailed Description:

Patients with scanty symptoms from their vascular malformation can do well with conservative treatment and / or with aids and adaptations in daily life. Compression therapy (elastic stockings), pain medication and good counseling is adequate for many. Patients with significant symptoms, however, may require more invasive treatment. Previously, it was common with surgical removal, but serious sequelae and frequent recurrence after surgery resulted in caution. Today it is more common with intervention radiology treatment with injection of sclerosing agents into existing malformation. This type of therapy almost always requires repeated treatment sequences, sometimes over several months. Treatment aims to seal blood vessels in the malformation and / or make the patient as possible symptoms. Recurrence occurs frequently and there are many who are not completely free from symptoms. Many patients have chronic problems with pain, wounds, bleeding and / or they have a cosmetically disfiguring condition. Predicting the performance of a specific type of treatment can be very difficult.

Until now, there are some studies that have considered the effect of bleomycin / pingyangmycin (China) and ethanol in the treatment of vascular malformations. To our knowledge there is no prospective or retrospective studies that compare the efficacy and side effects of bleomycin and sodium tetradecyl sulfate (Fibrovein ™) in the treatment of VM.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 126 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations
Study Start Date : August 2011
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Bleomycin + Fibrovein Drug: Bleomycin + Fibrovein
Other Name: Bleomycin Baxter + Fibrovein pharmaceutical products

Active Comparator: Bleomycin Drug: Bleomycin
Other Name: Bleomycin Baxter

Experimental: Natrium Tetradecyl Sulphate (Fibrovein ) Drug: Fibrovein
Other Name: Fibrovein S.T.D pharmaceutical products LTD

Primary Outcome Measures :
  1. Pain [ Time Frame: 1 year ]
    Pain will be measured before, during and after treatment. It will be asked about type, characteristics and intensity of pain. Using the VAS 0-10 will be used in this matter.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Venous malformation

Exclusion Criteria:

kidney and lung disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01347294

Layout table for location contacts
Contact: Rune Andersen, md +91564775

Layout table for location information
Oslo Universitetssykehus Rikshospitalet Recruiting
Oslo, Norway, 0227
Contact: Rune Andersen, MD    +4723073992   
Sponsors and Collaborators
Oslo University Hospital
Layout table for investigator information
Study Director: Andreas Abildgaard, phd Oslo Universitetssykehus, Rikshospitalet
Layout table for additonal information
Responsible Party: Rune Andersen, Consultant MD, Oslo University Hospital Identifier: NCT01347294    
Other Study ID Numbers: 1331TMF
TMF1331 ( Other Identifier: OsloUH )
First Posted: May 4, 2011    Key Record Dates
Last Update Posted: February 20, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Congenital Abnormalities
Antibiotics, Antineoplastic
Antineoplastic Agents